EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Resistance profiles of uropathogenic E. coli: ESBL and colistin in focus

Şafak Ceren Uçak, Ahmet Aktaş, D Bahar Akgün Karapınar, Yaşar Nakipoğlu, Betigül Öngen

The Journal of Infection in Developing Countries · 30.06.2026 · 20 (06) · 831-838

DOI: 10.3855/jidc.22195 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infection in Developing Countries, online erschienen am 30.06.2026. Verfasst von Şafak Ceren Uçak und 4 weiteren Autor:innen. Beteiligte Einrichtung: İstanbul University, İstanbul Faculty of Medicine, Medical Microbiology Department, İstanbul, Türkiye. Hauptthemen laut MEDLINE: Colistin, Anti-Bacterial Agents, Uropathogenic Escherichia coli, Escherichia coli Infections. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Escherichia coli is among the most common causes of urinary tract infections (UTIs), and the rise in extended-spectrum beta-lactamase (ESBL)-producing isolates is a growing concern because of increasingly limited treatment options. This study aimed to investigate the resistance profiles of ESBL-positive and -negative uropathogenic E. coli isolates to antibiotics used in treatment and colistin. Methodology: Urine samples sent to the Central Laboratory of Istanbul University, Istanbul Faculty of Medicine, for routine examination between September 2023 and January 2024 were included in the study. The presence of ESBL and susceptibility to antibiotics other than colistin were determined by the Vitek2 (bioMérieux, France) automated system, and colistin susceptibility was determined by the reference broth microdilution method.

Results

Of the 80 patients with E. coli, 80% were female, and 20% were male; 32.5% were children, and 67.5% were adults. All E. coli isolates were susceptible to nitrofurantoin, ertapenem, and meropenem. 40% of the strains were ESBL-positive. In respect of multidrug-resistant bacteria, among ESBL-positive and-negative isolates, 12.5% and 2.1% were resistant to six, 28.1% and 8.3% to five, 34.4% and 6.25% to four, and 18.75% and 16.7% to three different antibiotic groups, respectively. Of 80 E. coli strains, 92.5% of which were sensitive to colistin, the MIC50 value was 0.5 mg/L, and the MIC90 value was 2 mg/L.

Conclusions

Although the colistin resistance rate and minimum inhibitory concentration (MIC) values are not high, it is important to monitor resistance when treating problematic infections with multiple resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ColistinAnti-Bacterial AgentsUropathogenic Escherichia coliEscherichia coli InfectionsUrinary Tract Infectionsbeta-LactamasesDrug Resistance, Multiple, BacterialHumansFemaleMicrobial Sensitivity TestsMaleAdultChildMiddle AgedChild, PreschoolAdolescentTurkeyYoung AdultDrug Resistance, BacterialAgedInfant

Stichwörter der Autor:innen

E. coliESBLantimicrobial resistancecolistin

Substanzen

ColistinAnti-Bacterial Agentsbeta-Lactamases

Autor:innen und Institutionen

  • İstanbul University, İstanbul Faculty of Medicine, Medical Microbiology Department, İstanbul, Türkiye.

Zitieren

APA

Uçak, Ş. C., Aktaş, A., Akgün Karapınar, D. B., Nakipoğlu, Y., & Öngen, B. (2026). Resistance profiles of uropathogenic E. coli: ESBL and colistin in focus. The Journal of Infection in Developing Countries, 20(06), 831-838. https://doi.org/10.3855/jidc.22195

Vancouver

Uçak ŞC, Aktaş A, Akgün Karapınar DB, Nakipoğlu Y, Öngen B. Resistance profiles of uropathogenic E. coli: ESBL and colistin in focus. The Journal of Infection in Developing Countries. 2026;20(06):831-838. doi:10.3855/jidc.22195

BibTeX
@article{Uak2026,
  author = {Uçak, Şafak Ceren and Aktaş, Ahmet and Akgün Karapınar, D Bahar and Nakipoğlu, Yaşar and Öngen, Betigül},
  title = {Resistance profiles of uropathogenic E. coli: ESBL and colistin in focus},
  journal = {The Journal of Infection in Developing Countries},
  year = {2026},
  volume = {20},
  number = {06},
  pages = {831--838},
  doi = {10.3855/jidc.22195}
}
Kostenlos starten →